A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

Project: Research project

Project Details

StatusFinished
Effective start/end date4/30/14 → 5/1/16

Funding

  • Merck Sharp and Cohme Corporation: $60,900.00